418 results on '"Daneman, N."'
Search Results
2. Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study
- Author
-
Ernst P, Dahl M, Chateau D, Daneman N, Quail J, Sketris IS, Fisher A, Zhang J, and Bugden S
- Subjects
chronic obstructive pulmonary disease ,fluoroquinolones ,comparative effectiveness ,Diseases of the respiratory system ,RC705-779 - Abstract
Pierre Ernst,1 Matthew Dahl,2 Dan Chateau,2 Nick Daneman,3–6 Jacqueline Quail,7,8 Ingrid S Sketris,9 Anat Fisher,10 Jianguo Zhang,11 Shawn Bugden12,13 On behalf of the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators1Centre for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada; 2Manitoba Centre for Health Policy, Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada; 3Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; 4Sunnybrook Research Institute, Toronto, Ontario, Canada; 5Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; 6Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; 7Health Quality Council, Saskatoon, Saskatchewan, Canada; 8Department of Community Health & Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; 9College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada; 10Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada; 11Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 12School of Pharmacy, Memorial University of Newfoundland, St John’s, Newfoundland and Labrador, Canada; 13College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, CanadaCorrespondence: Shawn BugdenSchool of Pharmacy, Memorial University of Newfoundland, 300 Prince Philip Drive, St John’s, Newfoundland and Labrador A1B 3V6, CanadaTel +1-709-864-4400Fax +1-709-864-4819Email shawn.bugden@mun.caPurpose: Fluoroquinolone antibiotics are associated with rare, but severe adverse events. They are frequently used for the treatment of acute exacerbations of COPD (AECOPD). While their effectiveness in severe exacerbations requiring hospitalisation has been well documented, the potential benefit in the ambulatory setting is less clear, especially in uncomplicated patients with COPD.Patients and characteristics: We carried out a retrospective cohort study using health care databases from six Canadian provinces in subjects visiting their physician for uncomplicated COPD. Subjects dispensed either a quinolone or other antibiotics were compared using inverse probability of treatment weights with high dimensional propensity scores on 30-day outcomes, including repeat visits, hospitalisation for AECOPD and subsequent antibiotic prescription. Results from each province were combined by random effects meta-analysis.Results: We identified 286,866 AECOPD events among 203,642 unique individuals. The frequency of fluoroquinolone use, mostly levofloxacin and moxifloxacin, varied by province and ranged from 8% to 32% of AECOPD antibiotic prescriptions. The risk of a repeat ambulatory care visit was increased among patients who were dispensed a fluoroquinolone compared with other antibiotics (OR 1.32, 95% CI 1.27–1.36). The risk of a hospitalisation for AECOPD was also higher with fluoroquinolones (OR 1.52, 95% CI 1.33–1.74). There was no difference in subsequent antibiotic prescriptions (OR 1.00, 95% CI 0.94–1.07).Conclusion: There is no apparent benefit in short-term outcomes with fluoroquinolones as compared to other antibiotics for the ambulatory treatment of AECOPD in uncomplicated patients. These findings support current recommendations that fluoroquinolones be reserved for AECOPD in patients with recurrent exacerbations, significant co-morbidity or requiring hospitalisation.Keywords: chronic obstructive pulmonary disease, fluoroquinolones, comparative effectiveness
- Published
- 2019
3. The association of adequate empirical treatment and time to recovery from bacteraemic urinary tract infections: a retrospective cohort study
- Author
-
Wiggers, J.B., Sehgal, P., Pinto, R., MacFadden, D., and Daneman, N.
- Published
- 2019
- Full Text
- View/download PDF
4. Clinical and echocardiographic predictors of embolism in infective endocarditis: systematic review and meta-analysis
- Author
-
Yang, A., Tan, C., Daneman, N., Hansen, M.S., Habib, G., Salaun, E., Lavoute, C., Hubert, S., and Adhikari, N.K.J.
- Published
- 2019
- Full Text
- View/download PDF
5. Utility of prior cultures in predicting antibiotic resistance of bloodstream infections due to Gram-negative pathogens: a multicentre observational cohort study
- Author
-
MacFadden, D.R., Coburn, B., Shah, N., Robicsek, A., Savage, R., Elligsen, M., and Daneman, N.
- Published
- 2018
- Full Text
- View/download PDF
6. Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970
- Author
-
Khanafer, N., Daneman, N., Greene, T., Simor, A., Vanhems, P., Samore, M., and Brown, K.A.
- Published
- 2018
- Full Text
- View/download PDF
7. The predictors and economic burden of early-, mid- and late-onset cardiac implantable electronic device infections: a retrospective cohort study in Ontario, Canada
- Author
-
Daneman, N., Homenauth, E., Saskin, R., Ng, R., Ha, A., and Wijeysundera, H.C.
- Published
- 2020
- Full Text
- View/download PDF
8. Rationale and development of a business case for antimicrobial stewardship programs in acute care hospital settings
- Author
-
Morris, A. M., Rennert-May, E., Dalton, B., Daneman, N., Dresser, L., Fanella, S., Grant, J., Keynan, Y., Le Saux, N., McDonald, J., Shevchuk, Y., Thirion, D., and Conly, J. M.
- Published
- 2018
- Full Text
- View/download PDF
9. Real-world effectiveness of nirmatrelvir/ritonavir use for COVID-19: A population-based cohort study in Ontario, Canada
- Author
-
Schwartz, KL, primary, Wang, J, additional, Tadrous, M, additional, Langford, BJ, additional, Daneman, N, additional, Leung, V, additional, Gomes, T, additional, Friedman, L, additional, Daley, P, additional, and Brown, KA, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Additional file 1 of Rationale and development of a business case for antimicrobial stewardship programs in acute care hospital settings
- Author
-
Morris, A. M., Rennert-May, E., Dalton, B., Daneman, N., Dresser, L., Fanella, S., Grant, J., Keynan, Y., Le Saux, N., McDonald, J., Shevchuk, Y., Thirion, D., and Conly, J. M.
- Abstract
Appendix A. List of search terms for legislative requirements and human resource staffing requirements in antimicrobial stewardship programs. (DOCX 18 kb)
- Published
- 2023
- Full Text
- View/download PDF
11. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial
- Author
-
Florescu, S, Stanciu, D, Zaharia, M, Kosa, A, Codreanu, D, Kidwai, A, Masood, S, Kaye, C, Coutts, A, MacKay, L, Summers, C, Polgarova, P, Farahi, N, Fox, E, McWilliam, S, Hawcutt, D, Rad, L, O’Malley, L, Whitbread, J, Jones, D, Dore, R, Saunderson, P, Kelsall, O, Cowley, N, Wild, L, Thrush, J, Wood, H, Austin, K, Bélteczki, J, Magyar, I, Fazekas, Á, Kovács, S, Szőke, V, Donnelly, A, Kelly, M, Smyth, N, O’Kane, S, McClintock, D, Warnock, M, Campbell, R, McCallion, E, Azaiz, A, Charron, C, Godement, M, Geri, G, Vieillard-Baron, A, Johnson, P, McKenna, S, Hanley, J, Currie, A, Allen, B, McGoldrick, C, McMaster, M, Mani, A, Mathew, M, Kandeepan, R, Vignesh, C, TV, B, Ramakrishnan, N, James, A, Elvira, E, Jayakumar, D, Pratheema, R, Babu, S, Ebenezer, R, Krishnaoorthy, S, Ranganathan, L, Ganesan, M, Shree, M, Guilder, E, Butler, M, Cowdrey, K-A, Robertson, M, Ali, F, McMahon, E, Duffy, E, Chen, Y, Simmonds, C, McConnochie, R, O’Connor, C, El-Khawas, K, Richardson, A, Hill, D, Commons, R, Abdelkharim, H, Saxena, M, Muteithia, M, Dobell-Brown, K, Jha, R, Kalogirou, M, Ellis, C, Krishnamurthy, V, O’Connor, A, Thurairatnam, S, Mukherjee, D, Kaliappan, A, Vertue, M, Nicholson, A, Riches, J, Maloney, G, Kittridge, L, Solesbury, A, Ramos, A, Collins, D, Brickell, K, Reid, L, Smyth, M, Breen, P, Spain, S, Curley, G, McEvoy, N, Geoghegan, P, Clarke, J, Silversides, J, McGuigan, P, Ward, K, O’Neill, A, Finn, S, Wright, C, Green, J, Collins, É, Knott, C, Smith, J, Boschert, C, Slieker, K, Ewalds, E, Sanders, A, Wittenberg, W, Geurts, H, Poojara, L, Sara, T, Nand, K, Reeve, B, Dechert, W, Phillips, B, Oritz-Ruiz de Gordoa, L, Affleck, J, Shaikh, A, Murray, A, Ramanan, M, Frakking, T, Pinnell, J, Robinson, M, Gledhill, L, Wood, T, Sanghavi, R, Bhonagiri, D, Ford, M, Parikh, HG, Avard, B, Nourse, M, McDonald, B, Edmunds, N, Hoiting, O, Peters, M, Rengers, E, Evers, M, Prinssen, A, Morgan, M, Cole, J, Hill, H, Davies, M, Williams, A, Thomas, E, Davies, R, Wise, M, Grimm, P, Soukup, J, Wetzold, R, Löbel, M, Starke, L, Lellouche, F, Lizotte, P, Declerq, P, Antoine, M, Stephanie, G, Jean-Pierre, E, François, B, Marion, B, Philippe, R, Pourcine, F, Monchi, M, Luis, D, Mercier, R, Sagnier, A, Verrier, N, Caplin, C, Richecoeu, J, Combaux, D, Siami, S, Aparicio, C, Vautier, S, Jeblaoui, A, Lemaire-Brunel, D, D'Aragon, F, Carbonneau, E, Leblond, J, Plantefeve, G, Leparco, C, Contou, D, Fartoukh, M, Courtin, L, Labbe, V, Voiriot, G, Salhi, S, Chassé, M, Carrier, F, Boumahni, D, Benettaib, F, Ghamraoui, A, Sement, A, Gachet, A, Hanisch, A, Haffiane, A, Boivin, A-H, Barreau, A, Guerineau, E, Poupblanc, S, Egreteau, P, Lefevre, M, Bocher, S, Le Loup, G, Le Guen, L, Carn, V, Bertel, M, Antcliffe, D, Templeton, M, Rojo, R, Coghlan, P, Smee, J, Barker, G, Finn, A, Kreb, G, Hoff, U, Hinrichs, C, Nee, J, Mackay, E, Cort, J, Whileman, A, Spencer, T, Spittle, N, Beavis, S, Padmakumar, A, Dale, K, Hawes, J, Moakes, E, Gascoyne, R, Pritchard, K, Stevenson, L, Cooke, J, Nemeth-Roszpopa, K, Gauli, B, Bastola, S, Muller, G, Nay, M-A, Kamel, T, Benzekri, D, Jacquier, S, Runge, I, Mathonnet, A, Barbier, F, Bretagnol, A, Carter, J, Van Der Heyden, K, Mehrtens, J, Morris, A, Morgan, S, Burke, T, Mercier, E, Chartier, D, Salmon, C, Dequin, P-F, Garot, D, Bellemare, D, Cloutier, È, Daher, R, Costerousse, O, Boulanger, M-C, Couillard-Chénard, É, Lauzier, F, Francoeur, C, Francois, B, Gay, A, Anne-Laure, F, Ramali, M, HC, O, Ghosh, A, Osagie, R, Arachchige, M, Hartley, M, Cheung, W, Wong, H, Seigne, P, Eustace, J, O'Callaghan, A-M, O'Brien, F, Bamford, P, Reid, A, Cawley, K, Faulkner, M, Pickering, C, Raj, A, Tsinaslanidis, G, Khade, R, Agha, G, Sekiwala, R, Smith, T, Brewer, C, Gregory, J, Limb, J, Cowton, A, O’Brien, J, Postlethwaite, K, Malakouti, S, Music, E, Ricketts, D, King, A, Clermont, G, Bart, R, Mayr, F, Schoenling, A, Andreae, M, Shetty, V, Brant, E, Malley, B, Donadee, C, Sackrowitz, R, Weissman, A, Yealy, D, Barton, D, Talia, N, Nikitas, N, Wells, C, Lankester, L, McMillan, H, Van den Oever, H, Kruisdijk-Gerritsen, A, Haidar, G, Bain, W, Barbash, I, Fitzpatrick, M, Franz, C, Kitsios, G, Moghbeli, K, Rosborough, B, Shah, F, Suber, T, Pulletz, M, Williams, P, Birch, J, Wiseman, S, Horton, S, Alegria, A, Turki, S, Elsefi, T, Crisp, N, Allen, L, Truman, N, Smith, M, Chukkambotla, S, Goddard, W, Duberley, S, Khan, M, Kazi, A, Simpson, J, Duke, G, Chan, P, Carter, B, Hunter, S, Voigt, I, Schueler, R, Blank, E, Hüning, V, Steffen, M, Goralski, P, Litton, E, Regli, A, Pellicano, S, Palermo, A, Eroglu, E, Bihari, S, Laver, RD, Jin, X, Brown, J, McIntyre, J, French, C, Bates, S, Towns, M, Yang, Y, McGain, F, McCullagh, I, Cairns, T, Hanson, H, Patel, B, Clement, I, Evetts, G, Touma, O, Holland, S, Hodge, C, Taylor, H, Alderman, M, Barnes, N, Da Rocha, J, Smith, C, Brooks, N, Weerasinghe, T, Sinclair, J-A, Abusamra, Y, Doherty, R, Cudlipp, J, Singh, R, Yu, H, Daebis, A, Ng, C, Kendrick, S, Saran, A, Makky, A, Greener, D, Rowe-Leete, L, Edwards, A, Bland, Y, Dolman, R, Foster, T, Laffey, J, McNicholas, B, Scully, M, Casey, S, Kernan, M, Brennan, A, Rangan, R, Tully, R, Corbett, S, McCarthy, A, Duffy, O, Burke, D, Linnett, V, Sanderson, A, Ritzema, J, Wild, H, Lucas, R, Marriott, Y, Andric, Z, Cviljevic, S, Br, R, Zapalac, M, Mirković, G, Khare, D, Pinder, M, Gopinath, A, Kannan, T, Dean, S, Vanmali, P, Depuydt, P, De Waele, J, De Bus, L, Fierens, J, Bracke, S, Vermassen, J, Vermeiren, D, Pugh, R, Lean, R, Qiu, X, Scanlan, J, Evans, A, Davies, G, Lewis, J, Plesnikova, Y, Khoud, A, Coetzee, S, Puxty, K, Cathcart, S, Rimmer, D, Bagot, C, Scott, K, Martin, L, Yusuff, H, Isgro, G, Brightling, C, Bourne, M, Craner, M, Boyles, R, Alexander, B, Roberts, T, Nelli, A, Rosenstein-Sisson, R, Speyer, R, Pech, Y, McCullough, J, Tallott, M, Vazquez-Grande, G, Marten, N, Liu, T, Siddiqui, A, Khanal, S, Amatya, S, Szakmany, T, Cherian, S, Williams, G, James, C, Waters, A, Prout, R, Stedman, R, Davies, L, Pegler, S, Kyeremeh, L, Moorhouse, L, Arbane, G, Marotti, M, Bociek, A, Campos, S, Van Nieuwkoop, K, Ottens, T, Visser, Y, Van den Berg, L, Van der Kraan-Donker, A, Brett, S, Arias, S, Hall, R, Paneru, H, Koirala, S, Paudel, P, Wilson, M, Vaara, S, Pettilä, L, Heinonen, J, Pettilä, V, Jain, S, Gupta, A, Holbrook, C, Antoine, P, Meziani, F, Allam, H, Cattelan, J, Clere-Jehl, R, Helms, J, Kummerlen, C, Merdji, H, Monnier, A, Rahmani, H, Studer, A, Schneider, F, Castelain, V, Morel, G, L’Hotellier, S, Ochin, E, Vanjak, C, Rouge, P, Bendjemar, L, Albert, M, Serri, K, Cavayas, A, Duplaix, M, Williams, V, Catorze, NJTADS, Pereira, TNAL, Ferreira, RMC, Bastos, JMPS, Batista, TMO, Badie, J, Berdaguer, F, Malfroy, S, Mezher, C, Bourgoin, C, Moneger, G, Bouvier, E, Muñoz-Bermúdez, R, Marin-Corral, J, Degracia, A, Gómez, F, López, M, Aceto, R, Aghemo, A, Badalamenti, S, Brunetta, E, Cecconi, M, Ciccarelli, M, Constantini, E, Greco, M, Folci, M, Selmi, C, Voza, A, Henning, J, Bonner, S, Hugill, K, Cirstea, E, Wilkinson, D, Jones, J, Altomy, M, Karlikowski, M, Sutherland, H, Wilhelmsen, E, Woods, J, North, J, Pletz, M, Hagel, S, Ankert, J, Kolanos, S, Bloos, F, Simons, K, Van Zuylen, T, Bouman, A, Kumar, N, Panwar, R, Poulter, A-L, Sunkara, K, Szigligeti, G, Leszkoven, J, Rochwerg, B, Karachi, T, Oczkowski, S, Centofanti, J, Millen, T, Sundaran, D, Hollos, L, Turns, M, Walsh, J, Al Qasim, E, Alswaidan, L, Hegazy, M, Arishi, H, Al Amri, A, AlQahtani, S, Naidu, B, Tlayjeh, H, Hussain, S, Al Enezi, F, Abdukahil, SA, Hopkins, P, Noble, H, O’Reilly, K, Mehta, R, Wong, O, Makanju, E, Rao, D, Sikondari, N, Saha, S, Corcoran, E, Pappa, E, Cockrell, M, Donegan, C, Balaie, M, Nickoleit-Bitzenberger, D, Schaaf, B, Meermeier, W, Prebeg, K, Azzaui, H, Hower, M, Brieger, K-G, Elender, C, Sabelhaus, T, Riepe, A, Akamp, C, Kremling, J, Klein, D, Landsiedel-Mechenbier, E, Laha, S, Verlander, M, Jha, A, Megarbane, B, Voicu, S, Deye, N, Malissin, I, Sutterlin, L, Mrad, A, Lehalleur, A, Naim, G, Nguyen, P, Ekhérian, J-M, Boué, Y, Sidéris, G, Vodovar, D, Guérin, E, Grant, C, Brain, M, Mineall, S, Paramasivam, E, Wilby, E, Ogg, B, Howcroft, C, Aspinwall, A, Charlton, S, Gould, R, Mistry, D, Awan, S, Bedford, C, Carr-Wilkinson, J, Hall, A, Gardiner-Hill, C, Maloney, C, Brunskill, N, Watchorn, O, Hardy, C, Qureshi, H, Flint, N, Nicholson, S, Southin, S, Ghattaoraya, A, Harding, D, O’Halloran, S, Collins, A, Smith, E, Trues, E, Borgatta, B, Turner-Bone, I, Reddy, A, Wilding, L, Wilson, C, Surti, Z, Aneman, A, Miller, J, White, H, Estensen, K, Morrison, L, Sutton, J, Cooper, M, Warnapura, L, Agno, R, Sathianathan, P, Shaw, D, Ijaz, N, Spong, A, Sabaretnam, S, Burns, D, Lang, E, Tate, M, Fischer, R, Biradar, V, Soar, N, Golden, D, Davey, M, Seaman, R, Osborne, A, Bannard-Smith, J, Clark, R, Birchall, K, Henry, J, Pomeroy, F, Quayle, R, Wylie, K, Sukuraman, A, John, M, Sibin, S, Leditschke, A, Finnis, M, Jongebloed, K, Khwaja, K, Campisi, J, Van Vonderen, M, Pietersma, M, Vrolijk, L, Kampschreur, L, Van Gulik, L, Makowski, A, Misztal, B, Haider, S, Liao, A, Squires, R, Oborska, A, Kayani, A, Kalchko-Veyssal, S, Prabakaran, R, Hadebe, B, KalchkoVeyssal, S, Williams, T, Song, R, Morpeth, S, Lai, V, Habraken, H, Stewart, R, Mwaura, E, Mew, L, Wren, L, Willams, F, Sutherland, S-B, Rebello, R, Shehabi, Y, Al-Bassam, W, Hulley, A, Kadam, U, Sathianathan, K, Innes, R, Doble, P, Graham, L, Shovelton, C, Dean, T, Salahuddin, N, Aryal, D, Koirala, K, Rai, N, Luitel, S, Seppelt, I, Whitehead, C, Lowrey, J, Gresham, R, Masters, K, Hamlyn, V, Hawkins, N, Roynon-Reed, A, Cutler, S, Lewis, S, Lazaro, J, Newman, T, Aravindan, L, Asghar, A, Bartholomew, J, Bayne, M, Beddows, S, Birch, C, Brend, M, Byrne, R, Campbell, D, Campbell, H, Chambers, E, Clinton, A, Collins, J, Crawshaw, S, Dawson, LA, Donaldson, K, Drake, C, Dyas, S, Ellis, Y, Gilmour, K, Goodwin, J, Halden, S, Hall, AS, Hanson, J, Harper, H, Harrison, S, Hayes, A, Hodgson, H, Hurford, S-A, Jackson, S, Levett, C, Lock, S, Lockett, T, Logan, M, Lomme, K, Luo, J, Marsh, E, Mguni, N, Monaghan, H, Murphy, S, Muzengi, N, Naz, M, O'Kell, E, Oliver, A, O'Reilly, J, Pearson, K, Porter, D, Potter, A, Rook, C, Rounds, C, Sheffield, J, Shirley, K, Siewersk, C, Skinner, T, Speight, H, Sutu, M, Unsworth, A, Van’t Hoff, W, Walker, S, Williams, H, Williamson, D, Williamson, JD, Duan, E, Tsang, J, Patterson, L, Austin, P, Chapman, S, Cabrelli, L, Fletcher, S, Nortje, J, Fottrell-Gould, D, Randell, G, Stammers, K, Healey, G, Pinto, M, Borrill, Z, Duncan, T, Ustianowski, A, Uriel, A, Eltayeb, A, Alfonso, J, Hey, S, Shaw, J, Fox, C, Lindergard, G, Charles, B, Blackledge, B, Connolly, K, Harris, J, Cuesta, J, Xavier, K, Purohit, D, Elhassan, M, Haldeos, A, Vincent, R, Abdelrazik, M, Jenkins, S, Ganesan, A, Kumar, R, Carter, D, Bakthavatsalam, D, Frater, A, Saleem, M, Everitt, R, Hacking, D, Zaman, M, Elmahi, E, Jones, A, Hall, K, Phillips, M, Terrill, L, Mills, G, Raithatha, A, Bauchmuller, K, Ryalls, K, Harrington, K, Bowler, H, Sall, J, Bourne, R, Gross, J, Massey, N, Adebambo, O, Long, M, Tony, K, Juffermans, N, Koopmans, M, Dujardin, R, Alderink, B, Rowland, M, Hutton, P, Bashyal, A, Davidson, N, Hird, C, Chhablani, M, Phalod, G, Kirkby, A, Archer, S, Netherton, K, Reschreiter, H, Camsooksai, J, Patch, S, Humphrey, C, Flynn, G, Harrington, C, Kruger, P, Walsham, J, Meyer, J, Harward, M, Jones, C, Sathe, S, Roche, L, Davies, E, Skinner, D, Gaylard, J, Newman, J, Pogson, D, Rose, S, Daly, Z, Brimfield, L, Nown, A, Parekh, D, Bergin, C, Bates, M, McGhee, C, Lynch, D, Bhandal, K, Tsakiridou, K, Bamford, A, Cooper, L, Whitehouse, T, Veenith, T, Forster, E, O'Connell, M, Sim, M, Hay, S, Henderson, S, Nygren, M, Valentine, E, Katary, A, Bell, G, Wilcox, L, Mataliotakis, M, Smith, P, Ali, M, Isguzar, A, Phull, M-K, Zaidi, A, Pogreban, T, Rosaroso, L, Harvey, D, Lowe, B, Meredith, M, Ryan, L, Schouten, J, Pickkers, P, Roovers, N, Klop-Riehl, M, Van der Eng, H, Sloots-Cuppen, S, Preijers, L, Van Oosten, N, Moine, P, Heming, N, Maxime, V, Bossard, I, Nicholier, T, Clair, B, Orlikowski, D, Bounab, R, Abdeladim, L, Baker, S, Duroux, M, Ratcliffe, M, Sy, E, Mailman, J, Lee, S, Gupta, C, Kassir, S, López, R, Rodríguez-Gómez, J, Cárcel, S, Carmona, R, De la Fuente, C, Rodriguez, M, Jan Hassing, R, Greven, F, Huijbens, D, Roebers, L, Verheij, H, Miles, H, Attokaran, A, Buehner, U, Williams, E, Chapman, M, O’Connor, S, Glasby, K, Rivett, J, Brown, N, Kutsogiannis, D, Thompson, P, Rooney, K, Rodden, N, Thomson, N, McGlynn, D, Abel, L, Gemmell, L, Sundaram, R, Hornsby, J, Walden, A, Keating, L, Frise, M, Rai, S, Bartley, S, Schuster-Bruce, M, Pitts, S, Miln, R, Purandare, L, Vamplew, L, Dempster, D, Gummadi, M, Dormand, N, Wang, S, Spivey, M, Bean, S, Burt, K, Moore, L, Hammonds, F, Richards, C, Campbell, L, Smyth, K, Day, C, Zitter, L, Benyon, S, Singh, J, Lynch, C, Mikusek, J, Deacon, B, Turner, K, Baker, E, Hickey, J, Champanerkar, S, Aitken, L, LewisProsser, L, Ahmad, N, Wiles, M, Willson, J, Grecu, I, Martin, J, Wrey Brown, C, Arias, A-M, Bevan, E, Westlake, S, Craven, T, Hope, D, Singleton, J, Clark, S, McCulloch, C, Biddie, S, Welters, I, Hamilton, D, Williams, K, Waugh, V, Mulla, S, Waite, A, Roman, J, Martinez, M, Johnston, B, Puthucheary, Z, Martin, T, Santos, F, Uddin, R, Fernandez, M, Seidu, F, Somerville, A, Pakats, M-L, Begum, S, Shahid, T, Presneill, J, Barge, D, Byrne, K, Janin, P, Yarad, E, Bass, F, Hammond, N, Vuylsteke, A, Chan, C, Victor, S, Waterson, S, McNamara, R, Boardman, M, Gattas, D, Buhr, H, Coles, J, Matsa, R, Gellamucho, M, Creagh-Brown, B, Marriot, C, Salberg, A, Zouita, L, Stone, S, Michalak, N, Donlon, S, Mtuwa, S, Mayangao, I, Verula, J, Burda, D, Harris, C, Jones, E, Bradley, P, Tarr, E, Harden, L, Piercy, C, Nolan, J, Kerslake, I, Cook, T, Simpson, T, Dalton, J, Demetriou, C, Mitchard, S, Ramos, L, White, K, Johnson, T, Headdon, W, Spencer, S, White, A, Howie, L, Reay, M, Watts, A, Traverse, E, Jennings, S, Anumakonda, V, Tuckwell, C, Harrow, K, Matthews, J, McGarry, K, Moore, V, Smith, L, Summerfield, A, Dark, P, Harvey, A, Doonan, R, McMorrow, L, Knowles, K, Pendlebury, J, Perez, J, Marsden, T, Taylor, M, Michael, A, Collis, M, Claxton, A, Habeichi, W, Horner, D, Slaughter, M, Thomas, V, Proudfoot, N, Keatley, C, Donnison, P, Casey, R, Irving, B, Matimba-Mupaya, W, Reed, C, Anthony, A, Trim, F, Cambalova, L, Robertson, D, Wilson, A, Hulme, J, Kannan, S, Kinney, F, Senya, H, Ratnam, V, Gill, M, Kirk, J, Shelton, S, Schweikert, S, Wibrow, B, Anstey, M, Rauniyar, R, Khoso, N, Asif, N, Taqdees, H, Frey, C, Scano, R, McKee, M, Murphy, P, Thomas, M, Worner, R, Faulkner, B, Gendall, E, Hayes, K, Blakemore, H, Borislavova, B, Deshpande, K, Van Haren, F, Konecny, P, Inskip, D, Tung, R, Hayes, L, Murphy, L, Neill, A, Reidy, B, O’Dwyer, M, Ryan, D, Ainscough, K, Hamilton-Davies, C, Mfuko, C, Abbass, H, Mandadapu, V, Leaver, S, Patel, K, Farnell-Ward, S, Saluzzio, R, Rawlins, S, Sicat, C, De Keulenaer, B, Ferrier, J, Fysh, E, Davda, A, Mevavala, B, Cook, D, Clarke, F, Banach, D, Fernández de Pinedo Artaraz, Z, Cabreros, L, Latham, V, Kruisselbrink, R, Brochard, L, Burns, K, Sandhu, G, Khalid, I, White, I, Croft, M, Holland, N, Pereira, R, Nair, P, Buscher, H, Reynolds, C, Newman, S, Santamaria, J, Barbazza, L, Homes, J, Smith, R, Zaki, A, Johnson, D, Garrard, H, Juhaz, V, Brown, L, Pemberton, A, Roy, A, Rostron, A, Woods, L, Cornell, S, Fowler, R, Adhikari, N, Kamra, M, Marinoff, N, Garrett, P, Murray, L, Brailsford, J, Fennessy, G, Mulder, J, Morgan, R, Pillai, S, Harford, R, Ivatt, H, Evans, D, Richards, S, Roberts, E, Bowen, J, Ainsworth, J, Kuitunen, A, Karlsson, S, Vahtera, A, Kiiski, H, Ristimäki, S, Albrett, J, Jackson, C, Kirkham, S, Tamme, K, Reinhard, V, Ellervee, A, Põldots, L, Rennit, P, Svitškar, N, Browne, T, Grimwade, K, Goodson, J, Keet, O, Callender, O, Udy, A, McCracken, P, Young, M, Board, J, Martin, E, Kasipandian, V, Patel, A, Allibone, S, Mary-Genetu, R, English, S, Watpool, I, Porteous, R, Miezitis, S, McIntyre, L, Brady, K, Vale, C, Shekar, K, Lavana, J, Parmar, D, Peake, S, Kurenda, C, Hormis, A, Walker, R, Collier, D, Kimpton, S, Oakley, S, Bhagani, S, De Neef, M, Garcia, S, Maharajh, A, Nandani, A, Dobson, J, Fernando, G, Eastgate, C, Gomez, K, Abdi, Z, Tatham, K, Jhanji, S, Black, E, Dela Rosa, A, Howle, R, Baikady, R, Drummond, A, Dearden, J, Philbin, J, Munt, S, Gopal, S, Pooni, J-S, Ganguly, S, Smallwood, A, Metherell, S, Naeem, A, Fagan, L, Ryan, E, Mariappa, V, Foulds, A, Revill, A, Bhattarai, B, De Jonge, E, Wigbers, J, Del Prado, M, Cremer, O, Mulier, J, Peters, A, Romberg, B, Schutgens, R, Troeman, D, Van Opdorp, M, Besten, H, Brakké, K, Barber, R, Hilldrith, A, Kluge, S, Nierhaus, A, Jarczak, D, Roedl, K, Kochanek, M, Rueß-Paterno, G, Mc-Kenzie, J, Eichenauer, D, Shimabukuro-Vornhagen, A, Wilcox, E, Del Sorbo, L, Abdelhady, H, Romagnuolo, T, Simpson, S, Maiden, M, Horton, M, Trickey, J, Krajinovic, V, Kutleša, M, Kotarski, V, Brohi, F, Jagannathan, V, Clark, M, Purvis, S, Wetherill, B, Brajković, A, Babel, J, Sever, H, Dragija, L, Kušan, I, Dushianthan, A, Cusack, R, De Courcy-Golder, K, Salmon, K, Burnish, R, Smith, S, Ruiz, W, Duke, Z, Johns, M, Male, M, Gladas, K, Virdee, S, Swabe, J, Tomlinson, H, Rohde, G, Grünewaldt, A, Bojunga, J, Petros, S, Kunz, K, Schütze, B, Weismann, D, Frey, A, Drayss, M, Goebeler, ME, Flor, T, Fragner, G, Wahl, N, Totzke, J, Sayehli, C, Hakak, S, Altaf, W, O'Sullivan, M, Murphy, A, Walsh, L, Rega La Valle, A, Bewley, J, Sweet, K, Grimmer, L, Johnson, R, Wyatt, R, Morgan, K, Varghese, S, Willis, J, Stratton, E, Kyle, L, Putensen, D, Drury, K, Skorko, A, Bremmer, P, Ward, G, Bassford, C, Sligl, W, Baig, N, Rewa, O, Bagshaw, S, Basile, K, Stavor, D, Burbee, D, McNamara, A, Wunderley, R, Bensen, N, Adams, P, Vita, T, Buhay, M, Scholl, D, Gilliam, M, Winters, J, Doherty, K, Berryman, E, Ghaffari, M, Marroquin, O, Quinn, K, Garrard, W, Kalchthaler, K, Beard, G, Skrtich, A, Bagavathy, K, Drapola, D, Bryan-Morris, K, Arnold, J, Reynolds, B, Hussain, M, Dunsavage, J, Saiyed, S, Hernandez, E, Goldman, J, Brown, C, Comp, S, Raczek, J, Morris, J, Vargas Jr., J, Weiss, D, Hensley, J, Kochert, E, Wnuk, C, Nemeth, C, Mowery, B, Hutchinson, C, Winters, L, McAdams, D, Walker, G, Minnier, T, Wisniewski, M, Mayak, K, McCreary, E, Bariola, R, Viehman, A, Daley, J, Lopus, A, Schmidhofer, M, Ambrosino, R, Keen, S, Toffalo, S, Stambaugh, M, Trimmer, K, Perri, R, Casali, S, Medva, R, Massar, B, Beyerl, A, Burkey, J, Keeler, S, Lowery, M, Oncea, L, Daugherty, J, Sevilla, C, Woelke, A, Dice, J, Weber, L, Roth, J, Ferringer, C, Beer, D, Fesz, J, Carpio, L, Colin, G, Zinzoni, V, Maquigneau, N, Henri-Lagarrigue, M, Pouplet, C, Reill, L, Distler, M, Maselli, A, Martynoga, R, Trask, K, Butler, A, Attwood, B, Parsons, P, Campbell, B, Smith, A, Page, V, Zhao, X, Oza, D, Abrahamson, G, Sheath, B, Young, P, Young, C, Lesona, E, Navarra, L, Cruz, R, Delaney, K, Aguilar-Dano, A, Gojanovic, M, Rhodes, J, Anderson, T, Morris, S, Nayyar, V, Bowen, D, Kong, J, Joy, J, Fuchs, R, Lambert, B, Tai, C, Thomas, A, Keen, A, Tierney, C, Omer, N, Bacon, G, Tridente, A, Shuker, K, Anders, J, Greer, S, Scott, P, Millington, A, Buchanan, P, Binnie, A, Powell, E, McMillan, A, Luk, T, Aref, N, Denmade, C, Sadera, G, Jacob, R, Hughes, D, Sterba, M, Geng, W, Digby, S, Southern, D, Reddy, H, Hulse, S, Campbell, A, Garton, M, Watkins, C, Smuts, S, Quinn, A, Simpson, B, McMillan, C, Finch, C, Hill, C, Cooper, J, Budd, J, Small, C, O’Leary, R, Collins, E, Holland, A, Alexander, P, Felton, T, Ferguson, S, Sellers, K, Ward, L, Yates, D, Birkinshaw, I, Kell, K, Scott, Z, Pearson, H, Hashmi, M, Hassan, N, Panjwani, A, Umrani, Z, Shaikh, M, Ain, Q, Kanwal, D, Van Bree, S, Bouw-Ruiter, M, Osinga, M, Van Zanten, A, McEldrew, R, Rashan, S, Singh, V, Azergui, N, Bari, S, Beltran, M, Brugman, C, Groeneveld, E, Jafarzadeh, M, Keijzer-Timmers, N, Kester, E, Koelink, M, Kwakkenbos-Craanen, M, Okundaye, C, Parker, L, Peters, S, Post, S, Rietveld, I, Scheepstra-Beukers, I, Schreuder, G, Smit, A, Brillinger, N, Markgraf, R, Eichinger, F, Doran, P, Anjum, A, Best-Lane, J, Barton, F, Miller, L, Richards-Belle, A, Saull, M, Sprinckmoller, S, Wiley, D, Darnell, R, Au, C, Lindstrum, K, Cheng, A, Forbes, A, Heritier, S, Trapani, T, Cuthbertson, B, Manoharan, V, Dondrop, A, Tolppa, T, Ehrmann, S, Hullegie, S, Povoa, P, Beasley, R, Daneman, N, McGloughlin, S, Paterson, D, Venkatesh, B, De Jong, M, Uyeki, T, Baillie, K, Netea, M, Orr, K, Patanwala, A, Tong, S, Cooper, N, Galea, J, Leavis, H, Ogungbenro, K, Patawala, A, Rademaker, E, Youngstein, T, Carrier, M, Fergusson, D, Hunt, B, Kumar, A, Laffan, M, Lother, S, Middeldorp, S, Stanworth, S, De Man, A, Masse, M-H, Abraham, J, Arnold, D, Begin, P, Charlewood, R, Chasse, M, Coyne, M, Daly, J, Gosbell, I, Harvala-Simmonds, H, MacLennan, S, McDyer, J, Menon, D, Pridee, N, Roberts, D, Thomas, H, Tinmouth, A, Triulzi, D, Walsh, T, Wood, E, Calfee, C, O’Kane, C, Shyamsundar, M, Sinha, P, Thompson, T, Young, I, Burrell, A, Ferguson, N, Hodgson, C, Orford, N, Phua, J, Baron, R, Epelman, S, Frankfurter, C, Gommans, F, Kim, E, Leaf, D, Vaduganathan, M, Van Kimmenade, R, Sanil, A, Van Beurden, M, Effelaar, E, Schotsman, J, Boyd, C, Harland, C, Shearer, A, Wren, J, Attanayaka, U, Darshana, S, Ishani, P, Udayanga, I, Higgins, AM, Berry, LR, Lorenzi, E, Murthy, S, McQuilten, Z, Mouncey, PR, Al-Beidh, F, Annane, D, Arabi, YM, Beane, A, Van Bentum-Puijk, W, Bhimani, Z, Bonten, MJM, Bradbury, CA, Brunkhorst, FM, Buzgau, A, Buxton, M, Charles, WN, Cove, M, Detry, MA, Estcourt, LJ, Fagbodun, EO, Fitzgerald, M, Girard, TD, Goligher, EC, Goossens, H, Haniffa, R, Hills, T, Horvat, CM, Huang, DT, Ichihara, N, Lamontagne, F, Marshall, JC, McAuley, DF, McGlothlin, A, McGuinness, SP, McVerry, BJ, Neal, MD, Nichol, AD, Parke, RL, Parker, JC, Parry-Billings, K, Peters, SEC, Reyes, LF, Rowan, KM, Saito, H, Santos, MS, Saunders, CT, Serpa-Neto, A, Seymour, CW, Shankar-Hari, M, Stronach, LM, Turgeon, AF, Turner, AM, Van de Veerdonk, FL, Zarychanski, R, Green, C, Lewis, RJ, Angus, DC, McArthur, CJ, Berry, S, Derde, LPG, Gordon, AC, Webb, SA, Lawler, PR, Comm REMAP-CAP Investigators, Apollo - University of Cambridge Repository, Intensive Care Medicine, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Raymond Poincaré [Garches], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pittsburgh Foundation, PF, Amgen, Health Research Board, HRB: CTN 2014-012, Horizon 2020 Framework Programme, H2020: 101003589, Translational Breast Cancer Research Consortium, TBCRC, Canadian Institutes of Health Research, IRSC: 158584, Heart and Stroke Foundation of Canada, HSF, National Institute for Health and Care Research, NIHR, European Commission, EC, National Health and Medical Research Council, NHMRC: 1101719, APP194811, CS-2016-16-011, GNT2008447, RP-2015-06-18, Office of Health and Medical Research, OHMR, Health Research Council of New Zealand, HRC: 16/631, Eisai, Ministère des Affaires Sociales et de la Santé: PHRC-20-0147, Université Pierre et Marie Curie, UPMC, NIHR Imperial Biomedical Research Centre, BRC, Minderoo Foundation, Funding/Support : The Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Union’s Horizon 2020 research and innovation programme (#101003589), the Australian National Health and Medical Research Council (#APP1101719), the Australian Medical Research Future Fund (#APP2002132), the Health Research Council of New Zealand (#16/631), the Canadian Institutes of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant (#158584) and the Canadian Institute of Health Research COVID-19 Rapid Research Funding (#447335), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the UPMC Learning While Doing Program, the Translational Breast Cancer Research Consortium, the French Ministry of Health (PHRC-20-0147), the Wellcome Trust Innovations Project (215522), the Minderoo Foundation, the EU Programme Emergency Support Instrument, the NHS Blood and Transplant Research and Development Programme, the Translational Breast Cancer Research Consortium, the NSW Office of Health and Medical Research, Amgen, Eisai, and the Pittsburgh Foundation. Dr Higgins is funded by an NHMRC Emerging Leadership Fellowship (GNT2008447). Dr McQuilten is funded by an NHMRC Emerging Leadership Fellowship (APP194811). Dr Gordon is funded by an NIHR Research Professorship (RP-2015-06-18) and Dr Shankar-Hari by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). Dr Turgeon is the Chairholder of the Canada Research Chair in Critical Care Neurology and Trauma. Dr Lawler is supported by a career award from the Heart and Stroke Foundation of Canada., and European Project: 602525,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,PREPARE(2014)
- Subjects
Adult ,Male ,corticosteroid ,[SDV]Life Sciences [q-bio] ,Critical Illness ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,antiplatelet ,Lopinavir ,Adaptive platform trial randomized controlled trial intensive care, pneumonia COVID-19 antiplatelet immunoglobulin antiviral corticosteroid immune modulation anticoagulation ,All institutes and research themes of the Radboud University Medical Center ,Adrenal Cortex Hormones ,Humans ,anticoagulation ,intensive care, pneumonia ,COVID-19 Serotherapy ,Original Investigation ,Medicine(all) ,immune modulation ,Ritonavir ,SARS-CoV-2 ,COVID-19 ,Anticoagulants ,Bayes Theorem ,General Medicine ,Middle Aged ,antiviral ,Receptors, Interleukin-6 ,Adaptive platform trial ,randomized controlled trial ,Female ,Human medicine ,immunoglobulin ,Follow-Up Studies ,Hydroxychloroquine - Abstract
ImportanceThe longer-term effects of therapies for the treatment of critically ill patients with COVID-19 are unknown.ObjectiveTo determine the effect of multiple interventions for critically ill adults with COVID-19 on longer-term outcomes.Design, Setting, and ParticipantsPrespecified secondary analysis of an ongoing adaptive platform trial (REMAP-CAP) testing interventions within multiple therapeutic domains in which 4869 critically ill adult patients with COVID-19 were enrolled between March 9, 2020, and June 22, 2021, from 197 sites in 14 countries. The final 180-day follow-up was completed on March 2, 2022.InterventionsPatients were randomized to receive 1 or more interventions within 6 treatment domains: immune modulators (n = 2274), convalescent plasma (n = 2011), antiplatelet therapy (n = 1557), anticoagulation (n = 1033), antivirals (n = 726), and corticosteroids (n = 401).Main Outcomes and MeasuresThe main outcome was survival through day 180, analyzed using a bayesian piecewise exponential model. A hazard ratio (HR) less than 1 represented improved survival (superiority), while an HR greater than 1 represented worsened survival (harm); futility was represented by a relative improvement less than 20% in outcome, shown by an HR greater than 0.83.ResultsAmong 4869 randomized patients (mean age, 59.3 years; 1537 [32.1%] women), 4107 (84.3%) had known vital status and 2590 (63.1%) were alive at day 180. IL-6 receptor antagonists had a greater than 99.9% probability of improving 6-month survival (adjusted HR, 0.74 [95% credible interval {CrI}, 0.61-0.90]) and antiplatelet agents had a 95% probability of improving 6-month survival (adjusted HR, 0.85 [95% CrI, 0.71-1.03]) compared with the control, while the probability of trial-defined statistical futility (HR >0.83) was high for therapeutic anticoagulation (99.9%; HR, 1.13 [95% CrI, 0.93-1.42]), convalescent plasma (99.2%; HR, 0.99 [95% CrI, 0.86-1.14]), and lopinavir-ritonavir (96.6%; HR, 1.06 [95% CrI, 0.82-1.38]) and the probabilities of harm from hydroxychloroquine (96.9%; HR, 1.51 [95% CrI, 0.98-2.29]) and the combination of lopinavir-ritonavir and hydroxychloroquine (96.8%; HR, 1.61 [95% CrI, 0.97-2.67]) were high. The corticosteroid domain was stopped early prior to reaching a predefined statistical trigger; there was a 57.1% to 61.6% probability of improving 6-month survival across varying hydrocortisone dosing strategies.Conclusions and RelevanceAmong critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.
- Published
- 2023
12. Antibiotic Resistance associated with the COVID-19 Pandemic: A Rapid Systematic Review
- Author
-
Langford, BJ, primary, Soucy, J-PR, additional, Leung, V, additional, So, M, additional, Kwan, ATH, additional, Portnoff, JS, additional, Bertagnolio, S, additional, Raybardhan, S, additional, MacFadden, D, additional, and Daneman, N, additional
- Published
- 2022
- Full Text
- View/download PDF
13. Decision-support models for empiric antibiotic selection in Gram-negative bloodstream infections
- Author
-
MacFadden, D.R., Coburn, B., Shah, N., Robicsek, A., Savage, R., Elligsen, M., and Daneman, N.
- Published
- 2019
- Full Text
- View/download PDF
14. Trends in Oxygen Level During Acute COVID-19 Infection in Patients Quarantining at Home
- Author
-
Gershon, A.S., primary, Patel, N., additional, Wu, R., additional, Liaqat, S., additional, Liaqat, D., additional, de Lara, E., additional, Mariakakis, A., additional, Simor, A., additional, Lam, P., additional, Masood, S., additional, Andany, N., additional, Daneman, N., additional, Chan, A., additional, To, T., additional, and Falk, T.H., additional
- Published
- 2022
- Full Text
- View/download PDF
15. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
- Author
-
Tong, S.Y.C., Mora, J., Bowen, A.C., Cheng, M.P., Daneman, N., Goodman, A.L., Heriot, G.S., Lee, T.C., Lewis, R.J., Lye, D.C., Mahar, R.K., Marsh, J., McGlothlin, A., McQuilten, Z., Morpeth, S.C., Paterson, D.L., Price, D.J., Roberts, J.A., Robinson, J.O., van Hal, S.J., Walls, G., Webb, S.A., Whiteway, L., Yahav, D., Davis, J.S., Anagnostou, N., Archuleta, S., Athan, E., Best, E., Bloomfield, M., Botheras, C., Bowen, A., Britton, P., Brown, K., Campbell, A., Carter, H., Cheng, M., Chew, K.L., Chong, R.L.M., Coombs, G., Daley, P., Davies, J., Davis, J., Dishon, Y., Dotel, R., Dunlop, A., Flack, F., Flanagan, K., Foo, H., Ghanem-Zoubi, N., Giulieri, S., Goodman, A., Grant, J., Gregson, D., Guy, S., Gwee, A., Hardy, E., Henderson, A., Heriot, G., Howden, B., Johnstone, J., Kalimuddin, S., de Kretser, D., Kwa, A., Lee, T., Legg, A., Lewis, R., Lumley, T., Lye, D., MacFadden, D., Mahar, R., Malhamé, I., Marks, M., Martinello, M., Matthews, G., McArthur, C., McKew, G., McMullan, B., Milliken, E., Morpeth, S., Murthy, S., Nourse, C., O’Sullivan, M., Paterson, D., Paul, M., Petersiel, N., Petrella, L., Price, D., Roberts, J., Rogers, B., Saville, B., Scheetz, M., Scheuerman, O., Schwartz, K., Smith, S., Snelling, T., Sommerville, C., Stewardson, A., Sud, A., Tong, S., Turner, T., van Hal, S., Vasilunas, N., Voss, L., Webb, R., Webb, S., Wilson, H., Wuerz, T., Tong, S.Y.C., Mora, J., Bowen, A.C., Cheng, M.P., Daneman, N., Goodman, A.L., Heriot, G.S., Lee, T.C., Lewis, R.J., Lye, D.C., Mahar, R.K., Marsh, J., McGlothlin, A., McQuilten, Z., Morpeth, S.C., Paterson, D.L., Price, D.J., Roberts, J.A., Robinson, J.O., van Hal, S.J., Walls, G., Webb, S.A., Whiteway, L., Yahav, D., Davis, J.S., Anagnostou, N., Archuleta, S., Athan, E., Best, E., Bloomfield, M., Botheras, C., Bowen, A., Britton, P., Brown, K., Campbell, A., Carter, H., Cheng, M., Chew, K.L., Chong, R.L.M., Coombs, G., Daley, P., Davies, J., Davis, J., Dishon, Y., Dotel, R., Dunlop, A., Flack, F., Flanagan, K., Foo, H., Ghanem-Zoubi, N., Giulieri, S., Goodman, A., Grant, J., Gregson, D., Guy, S., Gwee, A., Hardy, E., Henderson, A., Heriot, G., Howden, B., Johnstone, J., Kalimuddin, S., de Kretser, D., Kwa, A., Lee, T., Legg, A., Lewis, R., Lumley, T., Lye, D., MacFadden, D., Mahar, R., Malhamé, I., Marks, M., Martinello, M., Matthews, G., McArthur, C., McKew, G., McMullan, B., Milliken, E., Morpeth, S., Murthy, S., Nourse, C., O’Sullivan, M., Paterson, D., Paul, M., Petersiel, N., Petrella, L., Price, D., Roberts, J., Rogers, B., Saville, B., Scheetz, M., Scheuerman, O., Schwartz, K., Smith, S., Snelling, T., Sommerville, C., Stewardson, A., Sud, A., Tong, S., Turner, T., van Hal, S., Vasilunas, N., Voss, L., Webb, R., Webb, S., Wilson, H., and Wuerz, T.
- Abstract
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Here we provide the rationale and framework for an adaptive platform trial applied to SAB infections. We detail the design features of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial that will enable multiple questions to be answered as efficiently as possible. The SNAP trial commenced enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficiency of clinical trials for other infectious disease syndromes.
- Published
- 2022
16. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
- Author
-
Tong, SYC, Mora, J, Bowen, AC, Cheng, MP, Daneman, N, Goodman, AL, Heriot, GS, Lee, TC, Lewis, RJ, Lye, DC, Mahar, RK, Marsh, J, McGlothlin, A, McQuilten, Z, Morpeth, SC, Paterson, DL, Price, DJ, Roberts, JA, Robinson, JO, van Hal, SJ, Walls, G, Webb, SA, Whiteway, L, Yahav, D, Davis, JS, Tong, SYC, Mora, J, Bowen, AC, Cheng, MP, Daneman, N, Goodman, AL, Heriot, GS, Lee, TC, Lewis, RJ, Lye, DC, Mahar, RK, Marsh, J, McGlothlin, A, McQuilten, Z, Morpeth, SC, Paterson, DL, Price, DJ, Roberts, JA, Robinson, JO, van Hal, SJ, Walls, G, Webb, SA, Whiteway, L, Yahav, D, and Davis, JS
- Abstract
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. The limited evidence base partly results from clinical trials for SAB infections being difficult to complete at scale using traditional clinical trial methods. Here we provide the rationale and framework for an adaptive platform trial applied to SAB infections. We detail the design features of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial that will enable multiple questions to be answered as efficiently as possible. The SNAP trial commenced enrolling patients across multiple countries in 2022 with an estimated target sample size of 7000 participants. This approach may serve as an exemplar to increase efficiency of clinical trials for other infectious disease syndromes.
- Published
- 2022
17. The economic burden of patient safety targets in acute care: a systematic review
- Author
-
Mittmann N, Koo M, Daneman N, McDonald A, Baker M, Matlow A, Krahn M, Shojanai KG, and Etchells E
- Subjects
Medicine (General) ,R5-920 - Abstract
Nicole Mittmann,1 Marika Koo,1 Nick Daneman,2 Andrew McDonald,3 Michael Baker,4 Anne Matlow,5 Murray Krahn,6 Kaveh Shojania,7 Edward Etchells71Health Outcomes and Pharmaco Economics (HOPE) Research Centre, Division of Clinical Pharmacology, 2Division of Infectious Diseases, 3Quality and Patient Safety, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 4Patient Safety in Ontario, University Health Network, Toronto, ON, Canada; 5Infection Prevention and Control and Patient Safety, Hospital for Sick Children, Toronto, ON, Canada; 6Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada; 7University of Toronto Centre for Patient Safety, Sunnybrook Health Sciences Centre, Toronto, ON, CanadaBackground: Our objective was to determine the quality of literature in costing of the economic burden of patient safety.Methods: We selected 15 types of patient safety targets for our systematic review. We searched the literature published between 2000 and 2010 using the following terms: “costs and cost analysis,” “cost-effectiveness,” “cost,” and “financial management, hospital.” We appraised the methodologic quality of potentially relevant studies using standard economic methods. We recorded results in the original currency, adjusted for inflation, and then converted to 2010 US dollars for comparative purposes (2010 US$1.00 = 2010 €0.76). The quality of each costing study per patient safety target was also evaluated.Results: We screened 1948 abstracts, and identified 158 potentially eligible studies, of which only 61 (39%) reported any costing methodology. In these 61 studies, we found wide estimates of the attributable costs of patient safety events ranging from $2830 to $10,074. In general hospital populations, the cost per case of hospital-acquired infection ranged from $2132 to $15,018. Nosocomial bloodstream infection was associated with costs ranging from $2604 to $22,414.Conclusion: There are wide variations in the estimates of economic burden due to differences in study methods and methodologic quality. Greater attention to methodologic standards for economic evaluations in patient safety is needed.Keywords: patient safety, burden of illness, review, quality
- Published
- 2012
18. Initial antimicrobial management of sepsis
- Author
-
Niederman, M.S., Baron, R.M., Bouadma, L., Calandra, T., Daneman, N., DeWaele, J., Kollef, M.H., Lipman, J., and Nair, G.B.
- Subjects
food and beverages ,Antibiotic therapy ,Antimicrobial therapy ,Bacteremia ,Biomarkers ,Fungal infection ,Intra-abdominal infection ,Pharmacokinetics ,Pneumonia ,Sepsis - Abstract
Sepsis is a common consequence of infection, associated with a mortality rate > 25%. Although community-acquired sepsis is more common, hospital-acquired infection is more lethal. The most common site of infection is the lung, followed by abdominal infection, catheter-associated blood steam infection and urinary tract infection. Gram-negative sepsis is more common than gram-positive infection, but sepsis can also be due to fungal and viral pathogens. To reduce mortality, it is necessary to give immediate, empiric, broad-spectrum therapy to those with severe sepsis and/or shock, but this approach can drive antimicrobial overuse and resistance and should be accompanied by a commitment to de-escalation and antimicrobial stewardship. Biomarkers such a procalcitonin can provide decision support for antibiotic use, and may identify patients with a low likelihood of infection, and in some settings, can guide duration of antibiotic therapy. Sepsis can involve drug-resistant pathogens, and this often necessitates consideration of newer antimicrobial agents.
- Published
- 2021
19. The Effects of the Serious Illness Care Program (SICP) on Health Care Resource Utilization (HRU)
- Author
-
Muscedere, John, Truelove, Amber Hastings, Stockley, Denise, Fowler, Jennifer, Barrie, Carol, Hafid, A., Guenter, D., Gallagher, E., Howard, M., You, J., Nidumolu, A., Lagrotteria, A., Motehayerarani, A., Virk, N., Sinnarajah, A., Human, T., Ying, I., Wong, H., Cummings, G., Pattullo, A., Wang, J., Lee, J., Moffat, D., Grinman, M., Montgomery, C. L., Rolfson, D. B., Stelfox, H. T., Zuege, D., Zygun, D. A., Hudson, D., Opgenorth, D., Bagshaw, S. M., Laur, C., Bell, J., Valaitis, R., Ray, S., Keller, H., Prevett, C., Fang, H., Shkredova, D., Xie, F., Zoratti, M., Gordon, C., Adachi, J., Phillips, S., Richardson, J., Tang, A., Ma, C., Riehm, L., Kendell, C., Urquhart, R., Burge, F., Kotecha, J., Martin, M., Jorgensen, M., Han, H., Dubé, D., Gutman, G., Sussman, T., DeVries, B., Gahagan, J., Brotman, S., Koo, E., Wegier, P., Embuldeniya, G., Ansari, S., Kobewka, D., O’Connor, E., Wu, P., Steinberg, L., Bell, C., Walton, T., Colstello, J., van Walraven, C., Downar, J., Wu, P. E., Costello, J., Wu, R., Frost, D., Kawaguchi, S., Mahtani, R., Toor, H., Goldman, R., Myers, J., Forster, A., Hladkowicz, E., Taljaard, M., Bryson, G., Beaulé, P. E., Gagné, S., Hamilton, G., Huang, A., Joanisse, J. A., Lavallée, L. T., MacDonald, D., Moloo, H., Thavorn, K., Yang, H., Forster, A. J., McIsaac, D. I., Sypes, E. E., de Grood, C., Parsons Leigh, J., Clement, F. M., Niven, D. J., Bitschy, A. M., Donald, E., Ewing, G., Grande, G., Sawatzky, R., Stajduhar, K. I., Parascandalo, F., Yu-Hin Siu, H., Delleman, B., Langevin, J., Mangin, D., Fang, Q., Price, D., Chan, D., Ting Wang, H., Nguyen, Q. D., Menard, C. A., Morinville, A., Hirdes, J. P., Hebert, P., Singh, J., Swinton, M., Morrison, J. M., Laur, C. V., Ebad, M., Dubin, J. A., Chen, H., Curtis, L.J., Bell, J. J., Gramlich, L. M., Keller, H. H., Dionne, J., Duan, E., Clarke, F., Hand, L., Millen, T., Sandu, G., Hodder, J., Santos, M., Shah, S., Trembley, M., Gomes, B., Leclair, L., Montroy, K., Watpool, I., Porteous, R., Acres, S., Foster, D., Auld, F., Williams, V., Marchand, J., Campisi, J., Alam, N., Lebrassier, M., Thompson, P., Hewer, T., Gilles, D., Hunt, M., Georgescu, I., Boyd, T., Lys, J., Marten, N., Campbell, E., Bentall, T., Kavikondala, K., Willems, S., Panchbhaya, Z., Booth, J., Ruddell, S., Richter, B., Tassy, D., Jesso, R., Marinoff, N., Perez, A., Kaur, N., Campbell, T., Lizotte, P., Lavoie, L., Dionne, M., Saunders, L., Zytaruk, N., Heels-Ansdell, D., Johnstone, J., Cook, D., Quinn, K. L., Campitelli, M. A., Diong, C., Daneman, N., Stall, N., Morris, A. M., Detsky, A. S., Jeffs, L., Maxwell, C. J., Bell, C. M., Bronskill, S. E., Alghamdi, M., Baracos, V., Karvellas, C., Churchill, T., Khadaroo, R. G., Moorhouse, P., Sampalli, T., Bedford, L., Edwards, L., Gibson, R., Mallery, L., Taylor, D., Warner, G., Harnish, A., Law, V., Lawson, B. J., Wood, S., Buckler, M., Fernandes, P., Elliott, J., Stolee, P., Ali, G., Dunichand-Hoedl, A., Salim, S. Y., Mazurak, V. C., Baracos, V. E., Heckman, G. A., Hebert, P. C., Costa, A. P., Arthur, S. A., Jones, A., Salam-White, L., Tanner, D., Negm, A. M., Kennedy, C. C., Ioannidis, G., Gajic-Veljanoski, O., Thabane, L., Adachi, J. D., Marr, S., Lau, A., Atkinson, S., Petruccelli, D., DeBeer, J., Winemaker, M., Avram, V., Williams, D., Armstrong, D., Lumb, B., Panju, A., Papaioannou, A., Boucher, A., Haesebaert, J., Freitas, A., Adekpedjou, R., Landry, M., Bourassa, H., Dawn, S., Croteau, J., Légaré, F., Takaoka, A. M., Clarke, F. J., Shears, M. S., Muscedere, J., Cook, D. J., Lee, A., Bouchard, D. R., Sénéchal, M., Mayo, A., Hrubeniuk, T. J., Keshavarz, M., Robertson, C., Read, E. A., Norris, C M., Meyer, S. R., Zibdawi, M., Marshall, H. D., Moody, E. M., Martin-Misener, R., Hawken, E. R., Boyd, J. G., Im, J., Mak, S., Upshur, R., Steinbreg, L., Kuluski, K., Van Damme, J., Delvin, M-E., Medves, J., Woddhouse, K., Sakamoto, M. L., Durepos, P., Ploeg, J., Akhtar-Danesh, N., Punia, H., Kaasalainen, S., Hewston, P., Kennedy, C., Merom, D., Patterson, C., Sztramko, R., Trainor, L., Grenier, A., Woolhouse, M., Petrella, A.F.M., Heath, M., Hyland, B., Fan, M., Hamilton, M., Reding, R., Trbovich, P., O’Reilly, D. M., O’Donnell, S., Bruning, P., Donovan, J., Anoveros-Barrera, A., Coletta, G., Jakubowski, J., Pritchard, J. M., Werner, G. E., Hoben, M., Estabrooks, C. A., Leaker, H. R., Holroyd-Leduc, J., Fox, L., Smallbone, J., Stinchcombe, A., Wilson, K., Kortes-Miller, K., Rees-Milton, K. J., Hulbert, M., Turner, M. E., Berger, C., Anastassiades, T. P., Hopman, W. M., Adams, M. A., Powley, W. L., Holden, R. M., Grewal, K., Sheets, D., Smith, A. P., Trites, M., Kennedy, M., MacDonald, S., Sivarajah, L., Lamarche, L., Giangregorio, A., Radcliffe, S., Ioannidi, G., Negm, A., Connolly, M. S., Klein, J. M., Huber, J. S., Safaraz, S., Foster, A. J., Simpson, J. A., Brunt, K.R., Elfassy, M. D., Munshi, L., Mehta, N., Martinez Guasch, F., Kamen, C., Burry, L., Soong, C., Mehta, S., McKay, S., Yetman, L., Slayter, J., McCollum, A., McGibbon, C. A., Jarrett, P., Robinson, B., Kolyvas, A., McCloskey, R., Gionet, S., Scheme, E., Harris, B., D’Aoust, T. R., Shao, T., Egan, R., Muscedere, J. G., Milne, B., Fitzpatrick, M., Yingwei Peng, P., Parlow, J., and Johnson, A. P.
- Subjects
Abstracts - Published
- 2019
20. The association of hospital prevention processes and patient risk factors with the risk of Clostridium difficile infection: a population-based cohort study
- Author
-
Daneman, N, Guttmann, A, Wang, X, Ma, X, Gibson, D, and Stukel, TA
- Published
- 2015
- Full Text
- View/download PDF
21. Long-Term Sustainability and Acceptance of Antimicrobial Stewardship in Intensive Care
- Author
-
Sehgal, P., primary, Elligsen, M., additional, Lo, J., additional, Lam, P.W., additional, Leis, J.A., additional, Fowler, R., additional, Pinto, R., additional, and Daneman, N., additional
- Published
- 2021
- Full Text
- View/download PDF
22. The culture of follow-up blood cultures
- Author
-
Wiggers, J.B. and Daneman, N.
- Published
- 2020
- Full Text
- View/download PDF
23. A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards.
- Author
-
Whitlock R., Reynolds S., Rogers B.A., Shehabi Y., Shin P., Fowler R.A., Daneman N., Rishu A.H., Pinto R., Arabi Y., Belley-Cote E.P., Cirone R., Downing M., Cook D.J., Hall R., McGuinness S., McIntyre L., Muscedere J., Parke R., Whitlock R., Reynolds S., Rogers B.A., Shehabi Y., Shin P., Fowler R.A., Daneman N., Rishu A.H., Pinto R., Arabi Y., Belley-Cote E.P., Cirone R., Downing M., Cook D.J., Hall R., McGuinness S., McIntyre L., Muscedere J., and Parke R.
- Abstract
Background: The optimal treatment duration for patients with bloodstream infection is understudied. The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) pilot randomized clinical trial (RCT) determined that it was feasible to enroll and randomize intensive care unit (ICU) patients with bloodstream infection to 7 versus 14 days of treatment, and served as the vanguard for the ongoing BALANCE main RCT. We performed this BALANCE-Ward pilot RCT to examine the feasibility and impact of potentially extending the BALANCE main RCT to include patients hospitalized on non-ICU wards. Method(s): We conducted an open pilot RCT among a subset of six sites participating in the ongoing BALANCE RCT, randomizing patients with positive non-Staphylococcus aureus blood cultures on non-ICU wards to 7 versus 14 days of antibiotic treatment. The co-primary feasibility outcomes were recruitment rate and adherence to treatment duration protocol. We compared feasibility outcomes, patient/pathogen characteristics, and overall outcomes among those enrolled in this BALANCE-Ward and prior BALANCE-ICU pilot RCTs. We estimated the sample size and non-inferiority margin impacts of expanding the BALANCE main RCT to include non-ICU patients. Result(s): A total of 134 patients were recruited over 47 site-months (mean 2.9 patients/site-month, median 1.0, range 0.1-4.4 patients/site-month). The overall recruitment rate exceeded the BALANCE-ICU pilot RCT (mean 1.10 patients/site-month, p < 0.0001). Overall protocol adherence also exceeded the adherence in the BALANCE-ICU pilot RCT (125/134, 93% vs 89/115, 77%, p = 0.0003). BALANCE-Ward patients were older, with lower Sequential Organ Failure Assessment scores, and higher proportions of infections caused by Escherichia coli and genito-urinary sources of bloodstream infection. The BALANCE-Ward pilot RCT patients had an overall 90-day mortality rate of 17/133 (12.8%), which was comparable to the 90-day mortality rate in the I
- Published
- 2020
24. Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: Study protocol.
- Author
-
Shehabi Y., Muscedere J., Parke R., Reynolds S., Rogers B., Fowler R.A., Daneman N., Rishu A.H., Pinto R.L., Arabi Y.M., Cook D.J., Hall R., McGuinness S., Shehabi Y., Muscedere J., Parke R., Reynolds S., Rogers B., Fowler R.A., Daneman N., Rishu A.H., Pinto R.L., Arabi Y.M., Cook D.J., Hall R., and McGuinness S.
- Abstract
Introduction Bloodstream infections are a leading cause of mortality and morbidity; the duration of treatment for these infections is understudied. Methods and analysis We will conduct an international, multicentre randomised clinical trial of shorter (7 days) versus longer (14 days) antibiotic treatment among hospitalised patients with bloodstream infections. The trial will include 3626 patients across 60 hospitals and 6 countries. We will include patients with blood cultures confirming a pathogenic bacterium after hospital admission. Exclusion criteria will include patient factors (severe immunosuppression), infection site factors (endocarditis, osteomyelitis, undrained abscesses, infected prosthetic material) and pathogen factors (Staphylococcus aureus, Staphylococcus lugdunensis, Candida and contaminant organisms). We will leave the selection of specific antibiotics, doses and route of delivery to the discretion of treating physicians; no placebo control will be used given the diversity of pathogens and sources of bacteraemia. The intervention will be assignment of treatment duration to be 7 versus 14 days. We will minimise selection bias via central randomisation with variable block sizes, with concealed allocation until day 7 of adequate antibiotic treatment. The primary outcome is 90-day survival; we will test whether 7 days is non-inferior to 14 days of treatment, with a non-inferiority margin of 4% absolute mortality. Secondary outcomes include hospital and intensive care unit (ICU) mortality, relapse rates of bacteraemia, hospital and ICU length of stay, mechanical ventilation and vasopressor duration, antibiotic-free days, Clostridium difficile infection, antibiotic allergy and adverse events and colonisation/infection with antibiotic-resistant organisms. Ethics and dissemination The study has been approved by the ethics review board at each participating site. Sunnybrook Health Sciences Centre is the central ethics committee. We will disseminate study re
- Published
- 2020
25. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management
- Author
-
Daneman, N., McGeer, A., Green, K., and Low, D.E.
- Subjects
Pneumococcal infections -- Care and treatment ,Pneumococcal infections -- Research ,Streptococcus pneumoniae -- Research ,Streptococcus pneumoniae -- Care and treatment ,Streptococcus pneumoniae -- Health aspects ,Patients -- Care and treatment ,Patients -- Management ,Company business management ,Health ,Health care industry - Published
- 2006
26. Hospital-acquired invasive group a streptococcal infections in Ontario, Canada, 1992-2000
- Author
-
Daneman, N., McGeer, A., Low, D.E., Tyrrell, G., Simor, A.E., McArthur, M., Schwartz, B., Jessamine, P., Croxford, R., and Green, K.A.
- Subjects
Hospital patients -- Health aspects ,Streptococcal infections -- Development and progression ,Streptococcal infections -- Diagnosis ,Isolation (Hospital care) ,Health ,Health care industry - Published
- 2005
27. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis
- Author
-
Murthy, S. K., Steinhart, A. H., Tinmouth, J., Austin, P. C., Daneman, N., and Nguyen, G. C.
- Published
- 2012
- Full Text
- View/download PDF
28. Defining the decision problem: a scoping review of economic evaluations for Clostridioides difficile interventions.
- Author
-
Richardson, M., Erman, A., Daneman, N., Miller, F.A., and Sander, B.
- Abstract
Background: Clostridioides difficile infection is the leading cause of healthcare-associated infectious diarrhoea. Several preventative and treatment interventions exist; however, decisions for their use are typically made independent of other interventions along the care pathway.Aim: To assess how the scope of the decision problem is defined in economic evaluations of C. difficile interventions.Methods: A scoping review was conducted following the Joanna Briggs Institute framework using a comprehensive literature search with C. difficile and economic evaluation as key search concepts. Study selection and extraction were performed independently by two reviewers. An in-depth analysis of all cost-utility and cost-effectiveness analyses was conducted. Care pathway domains (i.e. infection prevention and control, antimicrobial stewardship programmes, prevention, diagnostics, treatment) were defined iteratively, and each study was classified according to the scope of the decision problem: (i) one intervention, one domain; (ii) one intervention, multiple domains; (iii) multiple interventions, one domain; and (iv) multiple interventions, multiple domains.Results: In total, 3886 studies were identified. Of these, 116 studies were included in the descriptive overview, and 46 were included in the in-depth analysis. Most studies limited the scope of the decision problem to one intervention (43/46; 93%). Only three studies (3/46; 7%) assessed multiple interventions - either as bundled vs standalone interventions for prevention (i.e. a single domain), or as sequences of treatments for initial and recurrent infection (i.e. multiple domains). No study assessed multiple interventions across prevention and treatment domains.Conclusions: Economic evaluations for C. difficile infection assess narrowly defined decision problems which may have implications for optimal healthcare resource allocation. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
29. Long-Term Macrolide Therapy for Chronic Obstructive Pulmonary Disease: A Longitudinal Population-Based Study
- Author
-
Yan, M., primary, Saxena, F.E., additional, Calzavara, A., additional, Brown, K.A., additional, Garber, G., additional, Gershon, A.S., additional, Johnstone, J., additional, Kumar, M., additional, Langford, B.J., additional, Schwartz, K.L., additional, and Daneman, N., additional
- Published
- 2020
- Full Text
- View/download PDF
30. The second-hand effects of antibiotics: communicating the public health risks of drug resistance
- Author
-
Langford, B J, primary, Daneman, N, additional, Leung, V, additional, Wu, J H C, additional, Brown, K, additional, Schwartz, K L, additional, and Garber, G, additional
- Published
- 2019
- Full Text
- View/download PDF
31. Duration of therapy recommended for bacteraemic illness varies widely amongst clinicians.
- Author
-
Shehabi Y., Alwan M., Davis J.S., Daneman N., Fowler R., Rogers B., Shehabi Y., Alwan M., Davis J.S., Daneman N., Fowler R., and Rogers B.
- Abstract
The optimum duration of antimicrobial therapy would eradicate infection whilst minimising potential adverse drug effects to the patient. Australian and New Zealand infectious diseases (ID) and ICU specialists were surveyed regarding their recommended duration of antibiotic treatment for five common bacteraemic syndromes. A total of 239 clinicians responded to the survey (15.5% ICU and 84.5% ID). Overall, the most common reported durations were 7 (33.7%), 10 (25.9%) and 14 (26.0%) days, with 46% of responses recommending <=7 days. Most respondents (>75% for each characteristic) would not modify duration based on host characteristics such as patient age or co-morbidities. ID physicians recommended longer durations than ICU physicians for all five syndromes (ID, median 10, IQR 7-14, range 1-28 days; ICU, median 7, IQR 5-10, range 2-21 days). Across all respondents, the median (IQR) duration for each syndrome was: CVC-BSI, 7 (7-10) days; bacteraemic pneumonia, 7 (7-10) days; bacteraemic UTI, 10 (7-14) days; bacteraemic IAI, 7 (7-12) days; and bacteraemic SSTI, 10 (7-14) days. Marked variation exists amongst clinicians' recommended duration of antibiotic treatment for BSI. A proportion of clinicians recommend therapy of <=7 days at present (33.3-59.7% across scenarios). Patient characteristics are not strongly considered in the decision on therapy duration. This survey was undertaken as preparatory work for initiation of the BALANCE study, an ongoing randomised trial comparing 7 days with 14 days of therapy for BSI, providing an evidence base to inform best clinical treatment for this patient population.Copyright © 2019
- Published
- 2019
32. Additional file 1: of Rationale and development of a business case for antimicrobial stewardship programs in acute care hospital settings
- Author
-
Morris, A., Rennert-May, E., Dalton, B., Daneman, N., Dresser, L., Fanella, S., Grant, J., Keynan, Y., Le Saux, N., McDonald, J., Shevchuk, Y., Thirion, D., and Conly, J.
- Abstract
Appendix A. List of search terms for legislative requirements and human resource staffing requirements in antimicrobial stewardship programs. (DOCX 18 kb)
- Published
- 2018
- Full Text
- View/download PDF
33. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance
- Author
-
Harris, P. N. A., Tambyah, P. A., Lye, D. C., Mo, Y., Lee, T. H., Yilmaz, M., Alenazi, T. H., Arabi, Y., Falcone, M., Bassetti, M., Righi, E., Rogers, B. A., Kanj, S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T. H., Looke, D., Miyakis, S., Walls, G., Al Khamis, M., Zikri, A., Crowe, A., Ingram, P., Daneman, N., Griffin, P., Athan, E., Lorenc, P., Baker, P., Roberts, L., Beatson, S. A., Peleg, A. Y., Harris-Brown, T., Paterson, D. L., Mcnamara, J., Sieler, R., Garlick, J., Costa, J., Roney, J., Pratt, N., Tabaja, H., Kmeid, J., Tayyar, R., El Zein, S., Jones, S., Cowan, R., Tai, A., Lin, B., Rad, B., Macmorran, E., Pollard, J., Dinleyici, R., Istanbullu, A., Ceylan, B., Mert, A., Hashhoush, M., Dalwi, T., Korman, T., Azzam, R., Birrell, M., Hughes, C., Khan, S., Lau, J., Lee, L., Lim, K., Lin, Y. D., Lister, D., New, D., Rafiei, N., Stewart, J., Trad, M. A., Aye Yeung, V., Mcbride, S., Holland, D., Hopkins, C., Luey, C., Taylor, S., Morpeth, S., Finney, M., Martin, M., Holland, U., Ali, J., Jureen, R., Underwood, N., Henderson, A., Runnegar, N., Slavin, M., Robinson, O., Rishu, A., Shawkat, S., Fish, J., Chin Liew, K., Newton, P., Merelli, M., Carnelutti, A., Ussai, S., Pecori, D., Izharuddin, E., Young, B., Ding, Y., Ram, R., Kelly, J., Joshi, N., Richards, G., Smith, O., Alli, A., Vermeulen, I., Wright, B., Grey, C., Stewart, A., Reddy, D., Wasserman, S., Richi, H., Sultana, K., Alanazi, N., Bin Awad, E., Franzetti, F., Stolz, A., De Kock, E., Magongoa, T., Dutoit, M., Russo, A., Dentone, C., Eisen, D., and Heyer, L.
- Subjects
Adult ,Male ,Piperacillin ,Tazobactam Drug Combination ,Ceftriaxone ,Drug Resistance ,Bacterial ,Penicillanic Acid ,Bacteremia ,Meropenem ,Middle Aged ,Anti-Bacterial Agents ,Klebsiella Infections ,Klebsiella pneumoniae ,Cause of Death ,Escherichia coli ,Humans ,Female ,Thienamycins ,Aged ,Drug Resistance, Bacterial ,Escherichia coli Infections ,Piperacillin, Tazobactam Drug Combination - Published
- 2018
34. Selective Digestive Decontamination in the ICU: A Dynamic Population, Microsimulation Model
- Author
-
Schmidt, M., primary, Sahakyan, Y., additional, Cuthbertson, B.H., additional, Daneman, N., additional, Fowler, R., additional, Goddard, S., additional, Talla, R., additional, and Sander, B., additional
- Published
- 2019
- Full Text
- View/download PDF
35. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- Author
-
Harris, P.N.A., Tambyah, P.A., Lye, D.C., Mo, Y., Lee, T.H., Yilmaz, M., Alenazi, T.H., Arabi, Y., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T.H., Looke, D., Miyakis, S., Walls, G., Al Khamis, M., Zikri, A., Crowe, A., Ingram, P., Daneman, N., Griffin, P., Athan, E., Lorenc, P., Baker, P., Roberts, L., Beatson, S.A., Peleg, A.Y., Harris-Brown, T., Paterson, D.L., Robinson, J.O., Harris, P.N.A., Tambyah, P.A., Lye, D.C., Mo, Y., Lee, T.H., Yilmaz, M., Alenazi, T.H., Arabi, Y., Falcone, M., Bassetti, M., Righi, E., Rogers, B.A., Kanj, S., Bhally, H., Iredell, J., Mendelson, M., Boyles, T.H., Looke, D., Miyakis, S., Walls, G., Al Khamis, M., Zikri, A., Crowe, A., Ingram, P., Daneman, N., Griffin, P., Athan, E., Lorenc, P., Baker, P., Roberts, L., Beatson, S.A., Peleg, A.Y., Harris-Brown, T., Paterson, D.L., and Robinson, J.O.
- Abstract
Importance: Extended-spectrum β-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective “carbapenem-sparing” option to treat extended-spectrum β-lactamase producers. Objectives: To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. Design, Setting, and Participants: Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. Interventions: Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. Main Outcomes and Measures: The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. Results: Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6
- Published
- 2018
36. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance.
- Author
-
Pollard J., Arabi Y., Athan E., Lorenc P., Baker P., Roberts L., Beatson S.A., Peleg A.Y., Harris-Brown T., Paterson D.L., McNamara J., Sieler R., Garlick J., Costa J., Roney J., Pratt N., Tabaja H., Kmeid J., Tayyar R., El Zein S., Jones S., Cowan R., Lin B., Rad B., MacMorran E., Dinleyici R., Istanbullu A., Ceylan B., Mert A., Hashhoush M., Dalwi T., Korman T., Azzam R., Birrell M., Hughes C., Khan S., Lau J., Lee L., Lim K., Lin Y.D., Lister D., New D., Rafiei N., Stewart J., Tai A., Trad M.A., Aye Yeung V., McBride S., Holland D., Hopkins C., Luey C., Taylor S., Morpeth S., Finney M., Martin M., Holland U., Ali J., Jureen R., Underwood N., Henderson A., Runnegar N., Slavin M., Robinson O., Rishu A., Shawkat S., Fish J., Chin Liew K., Newton P., Merelli M., Carnelutti A., Ussai S., Pecori D., Izharuddin E., Young B., Ding Y., Ram R., Kelly J., Joshi N., Richards G., Smith O., Alli A., Vermeulen I., Wright B., Grey C., Stewart A., Reddy D., Wasserman S., Richi H., Sultana K., Alanazi N., Bin Awad E., Franzetti F., Stolz A., De Kock E., Magongoa T., Dutoit M., Russo A., Dentone C., Eisen D., Heyer L., Harris P.N.A., Tambyah P.A., Lye D.C., Mo Y., Lee T.H., Yilmaz M., Alenazi T.H., Falcone M., Bassetti M., Righi E., Rogers B.A., Kanj S., Bhally H., Iredell J., Mendelson M., Boyles T.H., Looke D., Miyakis S., Walls G., Al Khamis M., Zikri A., Crowe A., Ingram P., Daneman N., Griffin P., Pollard J., Arabi Y., Athan E., Lorenc P., Baker P., Roberts L., Beatson S.A., Peleg A.Y., Harris-Brown T., Paterson D.L., McNamara J., Sieler R., Garlick J., Costa J., Roney J., Pratt N., Tabaja H., Kmeid J., Tayyar R., El Zein S., Jones S., Cowan R., Lin B., Rad B., MacMorran E., Dinleyici R., Istanbullu A., Ceylan B., Mert A., Hashhoush M., Dalwi T., Korman T., Azzam R., Birrell M., Hughes C., Khan S., Lau J., Lee L., Lim K., Lin Y.D., Lister D., New D., Rafiei N., Stewart J., Tai A., Trad M.A., Aye Yeung V., McBride S., Holland D., Hopkins C., Luey C., Taylor S., Morpeth S., Finney M., Martin M., Holland U., Ali J., Jureen R., Underwood N., Henderson A., Runnegar N., Slavin M., Robinson O., Rishu A., Shawkat S., Fish J., Chin Liew K., Newton P., Merelli M., Carnelutti A., Ussai S., Pecori D., Izharuddin E., Young B., Ding Y., Ram R., Kelly J., Joshi N., Richards G., Smith O., Alli A., Vermeulen I., Wright B., Grey C., Stewart A., Reddy D., Wasserman S., Richi H., Sultana K., Alanazi N., Bin Awad E., Franzetti F., Stolz A., De Kock E., Magongoa T., Dutoit M., Russo A., Dentone C., Eisen D., Heyer L., Harris P.N.A., Tambyah P.A., Lye D.C., Mo Y., Lee T.H., Yilmaz M., Alenazi T.H., Falcone M., Bassetti M., Righi E., Rogers B.A., Kanj S., Bhally H., Iredell J., Mendelson M., Boyles T.H., Looke D., Miyakis S., Walls G., Al Khamis M., Zikri A., Crowe A., Ingram P., Daneman N., and Griffin P.
- Abstract
IMPORTANCE Extended-spectrum beta-lactamases mediate resistance to third-generation cephalosporins (eg, ceftriaxone) in Escherichia coli and Klebsiella pneumoniae. Significant infections caused by these strains are usually treated with carbapenems, potentially selecting for carbapenem resistance. Piperacillin-tazobactam may be an effective "carbapenem-sparing" option to treat extended-spectrum beta-lactamase producers. OBJECTIVES To determine whether definitive therapy with piperacillin-tazobactam is noninferior to meropenem (a carbapenem) in patients with bloodstream infection caused by ceftriaxone-nonsusceptible E coli or K pneumoniae. DESIGN, SETTING, AND PARTICIPANTS Noninferiority, parallel group, randomized clinical trial included hospitalized patients enrolled from 26 sites in 9 countries from February 2014 to July 2017. Adult patients were eligible if they had at least 1 positive blood culture with E coli or Klebsiella spp testing nonsusceptible to ceftriaxone but susceptible to piperacillin-tazobactam. Of 1646 patients screened, 391 were included in the study. INTERVENTIONS Patients were randomly assigned 1:1 to intravenous piperacillin-tazobactam, 4.5 g, every 6 hours (n = 188 participants) or meropenem, 1 g, every 8 hours (n = 191 participants) for a minimum of 4 days, up to a maximum of 14 days, with the total duration determined by the treating clinician. MAIN OUTCOMES AND MEASURES The primary outcome was all-cause mortality at 30 days after randomization. A noninferiority margin of 5% was used. RESULTS Among 379 patients (mean age, 66.5 years; 47.8% women) who were randomized appropriately, received at least 1 dose of study drug, and were included in the primary analysis population, 378 (99.7%) completed the trial and were assessed for the primary outcome. A total of 23 of 187 patients (12.3%) randomized to piperacillin-tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6
- Published
- 2018
37. Re: The impact of antibiotics on the Intestinal microbiota needs to be re-defined in order to optimize the antibiotic usage; by Ruppe et al.
- Author
-
Coburn, B., primary, Daneman, N., additional, MacFadden, D.R., additional, and Rooney, A., additional
- Published
- 2018
- Full Text
- View/download PDF
38. Influence of antibiotics and case exposure on hospital-acquired Clostridium difficile infection independent of illness severity
- Author
-
Forster, A.J., primary, Daneman, N., additional, and van Walraven, C., additional
- Published
- 2017
- Full Text
- View/download PDF
39. Re-evaluating the Inhibition of Stress Erosions (REVISE): a protocol for pilot randomized controlled trial
- Author
-
Alhazzani, W, Guyatt, G, Marshall, JC, Hall, R, Muscedere, J, Lauzier, F, Thabane, L, Alshahrani, M, English, SW, Arabi, YM, Deane, AM, Karachi, T, Rochwerg, B, Finfer, S, Daneman, N, Zytaruk, N, Heel-Ansdell, D, Cook, D, Alhazzani, W, Guyatt, G, Marshall, JC, Hall, R, Muscedere, J, Lauzier, F, Thabane, L, Alshahrani, M, English, SW, Arabi, YM, Deane, AM, Karachi, T, Rochwerg, B, Finfer, S, Daneman, N, Zytaruk, N, Heel-Ansdell, D, and Cook, D
- Abstract
INTRODUCTION: Clinicians routinely administer stress ulcer prophylaxis to mechanically ventilated patients in the intensive care unit (ICU), most commonly prescribing proton pump inhibitors (PPIs). However, the incidence of gastrointestinal (GI) bleeding from stress ulceration is low and recent observational studies suggest these agents may increase infections. Therefore, a large randomized clinical trial (RCT) is needed to inform modern practice. The aim of this multicenter pilot trial is to determine the feasibility of performing a large RCT to investigate the efficacy and safety of withholding intravenous pantoprazole. METHODS AND ANALYSIS: We will include adult critically ill patients who have an anticipated duration of ventilation of >=48 hours. We will exclude patients with acute or recent GI bleeding, pregnancy, dual antiplatelet therapy, poor prognosis or intent to withdraw life support, or previous enrolment in this or a confounding trial. Following informed consent, patients will be randomized to receive the intervention of placebo (0.9% NaCl) or intravenous pantoprazole 40 mg daily. Patients, families, clinicians, data collectors, adjudicators of outcome and statisticians will be blind to allocation. The three primary feasibility outcomes are the informed consent rate, recruitment rate, and protocol adherence. Clinical outcomes include clinically important upper GI bleeding, ventilator-associated pneumonia (VAP), Clostridium difficile infection, length of stay and mortality in ICU and hospital. ETHICS AND APPROVAL: This study has been approved by Health Canada, and research ethics board (REB) at each of the participating centers. TRIAL REGISTRATION NUMBER: This trial was registered on 31 October 2014. The trial registration number is NCT02290327. FUNDING: REVISE Pilot Trial is funded by Research Grant awarded by Physicians Services Incorporated, Dammam University Research Funds, Capital Health Authority Research Award Halifax, and Royal Adelaide Hospital
- Published
- 2016
40. Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study
- Author
-
Savage, R. D., primary, Fowler, R. A., additional, Rishu, A. H., additional, Bagshaw, S. M., additional, Cook, D., additional, Dodek, P., additional, Hall, R., additional, Kumar, A., additional, Lamontagne, F., additional, Lauzier, F., additional, Marshall, J., additional, Martin, C. M., additional, McIntyre, L., additional, Muscedere, J., additional, Reynolds, S., additional, Stelfox, H. T., additional, and Daneman, N., additional
- Published
- 2016
- Full Text
- View/download PDF
41. Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs
- Author
-
Maslikowska, J.A., primary, Walker, S.A.N., additional, Elligsen, M., additional, Mittmann, N., additional, Palmay, L., additional, Daneman, N., additional, and Simor, A., additional
- Published
- 2016
- Full Text
- View/download PDF
42. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
- Author
-
Daneman, N., primary, Lu, H., additional, and Redelmeier, D. A., additional
- Published
- 2015
- Full Text
- View/download PDF
43. The association of hospital prevention processes and patient risk factors with the risk ofClostridium difficileinfection: a population-based cohort study
- Author
-
Daneman, N, primary, Guttmann, A, additional, Wang, X, additional, Ma, X, additional, Gibson, D, additional, and Stukel, TA, additional
- Published
- 2015
- Full Text
- View/download PDF
44. Reply to Freyne et al
- Author
-
Palmay, L., primary, Pinto, R., additional, and Daneman, N., additional
- Published
- 2014
- Full Text
- View/download PDF
45. Hospital-wide Rollout of Antimicrobial Stewardship: A Stepped-Wedge Randomized Trial
- Author
-
Palmay, L., primary, Elligsen, M., additional, Walker, S. A. N., additional, Pinto, R., additional, Walker, S., additional, Einarson, T., additional, Simor, A., additional, Rachlis, A., additional, Mubareka, S., additional, and Daneman, N., additional
- Published
- 2014
- Full Text
- View/download PDF
46. Reply to Chironda et al
- Author
-
Leis, J. A., primary, Daneman, N., additional, Gold, W. L., additional, and McGeer, A., additional
- Published
- 2014
- Full Text
- View/download PDF
47. Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among Noncatheterized Inpatients: A Proof-of-Concept Study
- Author
-
Leis, J. A., primary, Rebick, G. W., additional, Daneman, N., additional, Gold, W. L., additional, Poutanen, S. M., additional, Lo, P., additional, Larocque, M., additional, Shojania, K. G., additional, and McGeer, A., additional
- Published
- 2014
- Full Text
- View/download PDF
48. The Co-Seasonality of Pneumonia and Influenza With Clostridium difficile Infection in the United States, 1993-2008
- Author
-
Brown, K. A., primary, Daneman, N., additional, Arora, P., additional, Moineddin, R., additional, and Fisman, D. N., additional
- Published
- 2013
- Full Text
- View/download PDF
49. Impact ofClostridium difficilecolitis on 5-year health outcomes in patients with ulcerative colitis
- Author
-
Murthy, S. K., primary, Steinhart, A. H., additional, Tinmouth, J., additional, Austin, P. C., additional, Daneman, N., additional, and Nguyen, G. C., additional
- Published
- 2012
- Full Text
- View/download PDF
50. Duration of Hospital Admission and the Need for Empirical Antipseudomonal Therapy
- Author
-
Daneman, N., primary, Elligsen, M., additional, Walker, S. A. N., additional, and Simor, A., additional
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.